
He spent 25 years learning how cancer drugs fail. Now he is running a company built on the idea that the next generation can be safer, steadier, and easier to live with.
Most antibody-drug conjugates carry one weapon. Callio is testing whether two coordinated payloads on the same HER2-targeted carrier can make resistant tumors run out of exits.